Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Hemnet Group Interim report Q2 2024

Summary for the period April-June 2024 · Net sales increased by 51.3 percent to SEK 405.0m (267.6) · EBITDA increased 53.7 percent to SEK 216.2m (140.7) · Operating profit increased 60.7 percent to SEK 195.6m (121.7) · ARPL, average revenue per listing, increased 51.6 percent to SEK 6,274 (4,138) Summary for the period January-June 2024 · Net sales increased by 43.8 percent to SEK 658.4m (457.7) · EBITDA increased 47.4 percent to SEK 335.9m (227.9) · Operating profit increased 55.2 percent to SEK 294.5m (189.8) · ARPL, average revenue per published listing,

NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A

· XTEND-Kids is the first assessment of once-weekly ALTUVOCT® prophylaxis in previously treated children · Results indicate highly effective bleed protection in children under 12 years of age with severe haemophilia A Sobi® today announced the publication of full results from the Phase 3 XTEND-Kids study in The New England Journal of Medicine (NEJM) confirming the safety and efficacy profile of ALTUVOCT® (efanesoctocog alfa), in children younger than 12 years old with severe haemophilia A. The study demonstrated that fixed-dose once-weekly prophylaxis with ALTUVOCT, a new class of

Implantica launches RefluxStop™ advanced education program in Spain

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, brings together top anti-reflux surgeons in Spain to create a community of excellence to share RefluxStop™ data, insights, and the best practices, driving advancements in the surgical treatment field of gastroesophageal reflux disease (GERD).During June and July 2024, more than 15 anti-reflux surgeons and gastroenterologists from seven leading reflux hospitals across Spain participated in RefluxStop™ advanced education events covering the latest clinical outcomes data, surgical

Getinge Interim Report April-June 2024: Higher sales, stronger margins and product launches with significant added value for customers

“Net sales increased by 15.7% in the second quarter, of which the organic increase was 8.9%,” says Mattias Perjos, President & CEO at Getinge. “The operating margin improved compared with last year due to strong sales and a positive product mix, which supports a solid financial position that enables investments in profitable growth.”Getinge’s order intake increased by 14.4%, of which organic growth was 7.8% due to positive performance in all business areas. Investments in the product portfolio is a fundamental piece of the medtech company’s strategy and during the quarter numerous important

Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The board of Enzymatica AB (publ) ("Enzymatica" or the "Company") has decided to carry out a rights issue of approximately SEK 130 million with preferential rights for existing shareholders (the “Rights issue”). The Rights issue is

Interim report 2024, January 1 – June 30

The second quarter saw continued robust revenue growth and improved profit. Organic growth remains burdened by challenging comparables from 2023 driven by very strong sales in pharmaceuticals and rental of equipment for clinical trials, but with organic order intake well back in positive territory with several large new orders, we are optimistic about the second half of the year. April – June 2024 Net revenue for the period was SEK 412.3 million (344.4), an increase of 19.7% On an organic basis, net revenue declined by 20.6% Orders received for the period was SEK 534.0 million (

Lagercrantz Interim Report Q1 2024/25

first quarter (1 April – 30 June 2024) · Net revenue increased by 10% to MSEK 2,253 (2,045). · Operating profit (EBITA) increased by 8% to MSEK 386 (357), where the EBITA margin was 17.1% (17.5). · Profit after financial items (EBT) increased by 9% to MSEK 302 (277). · Cash flow from operating activities amounted to MSEK 235 (286). · Profit after taxes increased by 6% to MSEK 222 (209). · Return on equity amounted to 26% (28) and the equity ratio was 36% (38). · Earnings per share for the latest 12-month period increased to SEK 4.32 (SEK 4.25 for the 2023/24 financial

SRV Half-year Report 1–6/2024: Operative operating profit increased driven by strong growth in revenue, the order backlog remains strong

SRV GROUP PLC     HALF-YEAR FINANCIAL REPORT      18 JULY 2024    AT 08.30 EESTSRV Half-year Report 1–6/2024: Operative operating profit increased driven by strong growth in revenue, the order backlog remains strong  April–June 2024 in brief: · Revenue amounted to EUR 186.3 (143.1) million (+30.2%). Revenue increased especially in alliance and project management contracts in business construction. Revenue from housing construction declined. · Operative operating profit amounted to EUR 1.5 (-3.9) million with an operating profit of EUR 1.5 (-3.0) million. Operative operating

Oriola Corporation’s Half-Year Report January-June 2024

Oriola Corporation Stock Exchange Release 18 July 2024 at 8.30 a.m. EEST Oriola Corporation’s Half-Year Report January-June 2024 Continued sales growth in both segments April-June 2024 highlights · Invoicing increased by 5.3 % to EUR 952.2 (904.3). On a constant currency basis, invoicing increased by 5.5% and was EUR 954.4 million. · Net sales increased by 13.0% to EUR 439.4 (389.0) million. On a constant currency basis, net sales increased by 13.3% and were EUR 440.6 million. · Adjusted EBIT was EUR 5.1 (3.4) million. On a constant currency basis, the adjusted EBIT was

Q2 2024 interim report January-June

Continued focus on operational improvements and product performance   Second quarter highlights >         Total reported Group net sales of SEK 4,485m (4,591) and total operating income before associated company income (ACI) and items affecting comparability (IAC) of SEK -70m (-273) >         2.6% organic sales growth for core operations (Nordics, Netherlands and Viaplay Select), with sales of SEK 4,292m (4,282) and operating income before ACI and IAC of SEK -72m (82) >         Total reported operating income of SEK 7m (-6,551) including ACI of SEK 28m (2) and IAC1 of SEK 48m

Fiskars Corporation Half-year Financial Report for January-June 2024

Fiskars CorporationHalf-year financial reportJuly 18, 2024 at 8:30 a.m. (EEST) Fiskars Corporation Half-year Financial Report for January-June 2024 Another solid quarter in challenging market conditions – accelerating efficiency improvements This release is a summary of the Fiskars Corporation’s Half-year Financial Report for January-June 2024 published today. The complete Half-year Financial Report with tables is attached to this release as a pdf-file. It is also available at https://fiskarsgroup.com/investors/reports-and-presentations/annual-and-interim-reports/ and on the

Dynavox Group Interim Report second quarter 2024

Dynavox Group AB (publ) today announced its results for the second quarter 2024. Comment from the Dynavox Group CEO Fredrik Ruben: We continue to grow sales at a rapid pace while investing in back-end systems and sales capacity to improve the scalability of the business. This is in line with our long-term goal of helping more people, combined with high growth and a stronger operating margin. The limited awareness of assistive communication continues to offer significant potential for us to achieve long-term growth and make a difference for many more individuals with communication

MTG maintains 2024 outlook and operating margin grows to 30%

Despite Q2 revenues declining by -1% on a reported basis in constant currencies, we are maintaining our full-year outlook of 1-5% growth in reported sales before currency effects. Snowprint’s revenues grew year over year thanks to the continued success of Warhammer 40,000: Tacticus, while our remaining studios’ sales declined. We remain focused on our established portfolio and maintain marketing discipline as we prepare to accelerate UA spend again on the back of new content for established titles and new games in H2. User acquisition spend was down year over year but increased again at the

Volvo Group – the second quarter 2024

“During Q2 2024, the Volvo Group delivered good profitability as demand in many markets continued to normalize compared with the high levels of 2023. Net sales amounted to SEK 140.2 billion, which adjusted for currency changes was on the same level as in the prior year. The adjusted operating income amounted to SEK 19.4 billion (21.9), with a margin of 13.9% (15.4). Lower volumes and our increased investments in R&D affected margins negatively, while carry-over from the price increases we implemented during last year continued to have a positive effect. Our service business grew by 5%

New findings could lead to safer, more stable metal batteries

Metal batteries have the potential to deliver more energy, at a lower weight, than the popular lithium-ion battery. The problem, however, is that the technology currently has too short a lifespan due to the highly reactive nature of the lithium metal within these batteries. New research from Chalmers University of Technology, Sweden, shows where the problems lie and how to overcome them by creating the metal electrode directly in the battery cell. Lithium-ion batteries are the most popular battery option today, but in a society facing widespread electrification, new battery

Half-year financial report of Atria Plc, 1 January–30 June 2024

Atria Plc, Half-year financial report, 18 July 2024, 8.00 amHalf-year financial report of Atria Plc, 1 January–30 June 2024 Atria’s good performance continued in April–June – the results of all business areas improvedApril–June 2024 · Consolidated net sales totalled EUR 454.3 million (EUR 457.2 million). Atria Finland's net sales decreased due to reduced Foodservice and feed sales. The net sales of Atria Sweden and Atria Denmark & Estonia grew. · Consolidated EBIT was EUR 18.4 million (EUR 10.0 million), or 4.0% (2.2%) of net sales. All business areas performed better than in

Interim Report, Quarter 2, 2024

Quarter 2, 2024 - Strong earnings and good underlying growth  · Net sales decreased 1.2% to SEK 36,617m (37,078) · Organic growth amounted to -0.9%, of which volume accounted for 0.4% and price/mix -1.3%. Excluding restructuring and exited contracts, volumes increased 2.9%. · EBITA increased 27% to SEK 5,237m (4,131) · EBITA excl. IAC increased 17% to SEK 5,398m (4,617) and the EBITA margin excl. IAC increased 2.2 percentage points to 14.7% (12.5) · ROCE increased to 17.9% (14.2), and ROCE excl. IAC increased 2.7 percentage points to 18.5% (15.8). · Operating cash flow

Volvo Cars reports record core operating profit of SEK 8.2 billion in Q2 2024

· Q2 operating profit (excl. JVs and associates) was SEK 8.2 bn, up 28 per cent vs Q2 2023 · Q2 operating profit was 8.0 bn SEK, up 60 per cent vs Q2 2023 · Q2 EBIT margin (excl. JVs and associates) was 8.1 per cent, vs 6.3 per cent in Q2 2023 · Q2 EBIT margin was 7.9 per cent, vs 4.9 per cent in Q2 2023 · Q2 revenue was 101.5 bn SEK, vs 102.2 bn SEK in Q2 2023 · Q2 basic earnings per share was 1.79 SEK, vs 1.12 SEK in Q2 2023 · Q2 electrified share of sales at 48 per cent, vs 39 per cent in Q2 2023 · Q2 fully electric car sales share at 26 per cent, vs 16 per cent in

Alma Media’s Half-Year Report January—June 2024: In Q2, revenue increased by 2.4%, supported by acquisitions and adjusted operating profit was on a par with the comparison period

Alma Media Corporation  Half-Year Report               18 July 2024 at 8.00 a.m. Alma Media’s Half-Year Report January—June 2024: In Q2, revenue increased by 2.4%, supported by acquisitions and adjusted operating profit was on a par with the comparison period Financial performance April—June 2024: · Revenue MEUR 80.1 (78.2), up 2.4%. · The share of digital business was 84.4% (82.6%) of revenue. · Adjusted operating profit MEUR 19.4 (19.4), or 24.2% (24.8%) of revenue. · Operating profit MEUR 19.2 (19.9), down 3.5%. · Alma Career: Revenue in local currencies was on a

Interim report January–June 2024 – Pricer AB

A new of quarter of profitability and strong cash flow from operating activitiesInterim report January–June 2024 – Pricer AB A new of quarter of profitability and strong cash flow from operating activities Second quarter 2024• Net sales amounted to SEK 644.0 M (687.2), a decrease of 6.3 percent compared to the same quarter last year.• Operating profit increased to SEK 48.5 M (-0.3), which corresponds to an operating margin of 7.5 percent (0.0).• Operating profit before depreciation, amortization and impairment rose to SEK 66.4 M (14.6).• Cash flow from operating activities

Telia Company Interim Report January – June 2024

Continued operational momentumSecond quarter summary –         Revenue increased 2.3% to SEK 22,380 million (21,877) and like for like, revenue increased 1.5%. –         Service revenue increased 3.3% to SEK 19,403 million (18,787) and like for like, service revenue increased 2.5%. For the Telco operations, service revenue increased 2.6% on a like for like basis. –         Adjusted EBITDA increased 6.4% to SEK 7,856 million (7,387) and like for like, adjusted EBITDA increased 5.3%. For the Telco operations, adjusted EBITDA increased 4.1% on a like for like basis. –

Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update

Lund, Sweden, July 18, 2024, Hansa Biopharma today announced its first half and second quarter 2024 financial results and business update. Søren Tulstrup, President and CEO, Hansa Biopharma said: “For the third consecutive quarter, Hansa Biopharma delivered solid IDEFIRIX[®] sales performance driven by continued utilization of IDEFIRIX in key transplant centers across all major European markets. Additionally, we continued to progress key trials across the pipeline. Notably, we completed randomization of all patients in ConfIdeS, our pivotal Phase 3 US trial in kidney transplantation, and

EQT AB (publ) Half-year Report 2024

Well positioned as markets improve “In the first half of 2024, EQT successfully closed several fundraisings, despite a challenging environment. We launched new strategies and further strengthened our private wealth platform. Investment activity continued at a good pace across strategies, and we are actively pursuing realizations, building on our strong track record of providing liquidity for our clients.” Christian Sinding, CEO and Managing PartnerHighlights for the period Jan-Jun 2024 (Jan-Jun 2023) Financial · During the period, management fees increased due to closed out

SKF interim report Q2 2024: Margin resilience in continued soft markets

Gothenburg, 18 July 2024 Q2 2024Net sales: SEK 25,606 million (27,123) Organic growth: −6.6% (7.9%), driven by lower market demand across regions and industries, except for aerospace and railway showing continuous growth.Adjusted operating profit: SEK 3,324 million (3,614). Continued strong price/mix contribution, driven by pricing actions and active portfolio management, as well as good cost control largely offset lower volumes.Adjusted operating margin: 13.0% (13.3%)Net cash flow from operations: SEK 2,152 (3,664) Rickard Gustafson, President and CEO: “We continue to

There are no items matching the current filter
There are no more items matching the current filter
Back to top